73 related articles for article (PubMed ID: 554636)
1. [Experimental models of immunochemotherapeutic synergism: study of the influence of the treatment schedule].
Circolo A; Bianchi R; Nardelli B; Romani L; Andrielli M
Boll Soc Ital Biol Sper; 1979 Oct; 55(19):1974-80. PubMed ID: 554636
[TBL] [Abstract][Full Text] [Related]
2. [Use of BCG as an immunoadjuvant in combination with antitumor agents in virus-induced leukemia].
Sbaraglia G; Cenci E; Vecchiarelli A; Perito S
Boll Soc Ital Biol Sper; 1980 Oct; 56(19):1969-75. PubMed ID: 7459108
[TBL] [Abstract][Full Text] [Related]
3. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.
Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E
Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813
[TBL] [Abstract][Full Text] [Related]
4. Combined effects of immunity and antitumor drugs against cancer. I. In vivo studies with cis-diamminedichloroplatinum and cyclophosphamide in mouse models.
Ricci F; De Filippi R; Riccardi C; Romani L; Giuliani A
Chemioterapia; 1987 Dec; 6(6):403-9. PubMed ID: 3435922
[TBL] [Abstract][Full Text] [Related]
5. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
6. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
7. [The use of BCG as immunoadjuvant in combination with antitumor drugs in a virus induced leukemia. II].
Perito S; Cenci E; Sbaraglia G; Vecchiarelli A
Boll Soc Ital Biol Sper; 1980 Dec; 56(23):2511-7. PubMed ID: 7470294
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A
Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450
[TBL] [Abstract][Full Text] [Related]
9. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
[TBL] [Abstract][Full Text] [Related]
10. [Antitumor activity of doxorubicin in the treatment of hemocytoblastosis La and various ascites tumors in mice].
Ul'ianova LA; Tarasova VE; Bazhanov VS; Iudina OI; Gol'dberg LE
Antibiotiki; 1984 Nov; 29(11):861-6. PubMed ID: 6524889
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines.
Nicolin A; Canti G; Marelli O; Veronese F; Goldin A
Cancer Res; 1981 Apr; 41(4):1358-62. PubMed ID: 7011535
[TBL] [Abstract][Full Text] [Related]
12. Relationships among tumor load, route of tumor inoculation, and response to immunochemotherapy in a murine lymphoma model.
Marconi P; Cassone A; Baccarini M; Tissi L; Garaci E; Bonmassar E; Frati L; Bistoni F
J Natl Cancer Inst; 1983 Aug; 71(2):299-307. PubMed ID: 6348362
[TBL] [Abstract][Full Text] [Related]
13. Combined effects of host antitumor immune responses and chemotherapy. Studies with hexamethylmelamine.
Tricarico M; Fuschiotti P; Ricci F; De Filippi R; Nunziata C; Pastore S; De Vecchis L
Chemioterapia; 1988 Jun; 7(3):203-7. PubMed ID: 3139307
[TBL] [Abstract][Full Text] [Related]
14. Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia.
McGovren JP
Cancer Treat Rep; 1980; 64(4-5):727-9. PubMed ID: 6448690
[TBL] [Abstract][Full Text] [Related]
15. [Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics by calcium channel blockers and calmodulin inhibitors].
Tsuruo T
Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):750-9. PubMed ID: 6585181
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.
Lin JM; Li B; Rimmer E; VanRoey M; Jooss K
Exp Hematol; 2008 Mar; 36(3):319-28. PubMed ID: 18279719
[TBL] [Abstract][Full Text] [Related]
17. Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstrated by plaque assay.
Fuji H; Mihich E
Cancer Res; 1975 Apr; 35(4):946-52. PubMed ID: 1090366
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia.
Li LH; Wallace TL; Richard KA; Tracey DE
Cancer Res; 1985 Feb; 45(2):532-8. PubMed ID: 3967227
[TBL] [Abstract][Full Text] [Related]
19. Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin.
Yokota S; Hara H; Luo Y; Seon BK
Cancer Res; 1990 Jan; 50(1):32-7. PubMed ID: 2293557
[TBL] [Abstract][Full Text] [Related]
20. In vivo antitumor activity of the bitter melon (Momordica charantia).
Jilka C; Strifler B; Fortner GW; Hays EF; Takemoto DJ
Cancer Res; 1983 Nov; 43(11):5151-5. PubMed ID: 6616452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
